Cookson Peirce & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cookson Peirce & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,060	Closed	-$351K	–	320
2026 Q1	$351K	Buy	1,060 +249	+31%	+$84.7K	0.01%	260
2025 Q4	$322K	Buy	811 +264	+48%	+$117K	0.01%	266
2025 Q3	$249K	Buy	+547	New	+$223K	0.01%	284
2022 Q2	–	Sell	-10,403	Closed	-$1.7M	–	184
2022 Q1	$1.7M	Buy	10,403 +675	+7%	+$103K	0.1%	101
2021 Q4	$1.65M	Buy	9,728 +500	+5%	+$92.9K	0.09%	101
2021 Q3	$1.74M	Buy	+9,228	New	+$1.73M	0.11%	99
2015 Q1	–	Sell	-2,535	Closed	-$246K	–	125
2014 Q4	$246K	Buy	+2,535	New	+$235K	0.05%	112

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Cookson Peirce & Co's ALNY Position: Q2 2026 in Review

Cookson Peirce & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 1,060 shares — an estimated $351K sold.

Cookson Peirce & Co first reported a position in ALNY in Q4 2014 and held it in 7 quarters. The position peaked at $1.74M in Q3 2021. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Cookson Peirce & Co reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Cookson Peirce & Co sold 1,060 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $351K.
Cookson Peirce & Co first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Cookson Peirce & Co's Alnylam Pharmaceuticals position peaked at $1.74M in Q3 2021.
149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cookson Peirce & Co's 13F filing for Q2 2026, filed 23 Jul 2026.